DarioHealth Corp. announced on January 14, 2025, a collaboration with MediOrbis, a multi-specialty digital health provider, to integrate prescribing capabilities into Dario's GLP-1 behavior change solution. This strategic addition creates a fully integrated medical weight loss program, expanding Dario's addressable market in the rapidly growing GLP-1 segment. The enhanced solution targets both employers and direct-to-consumer markets.
The collaboration addresses the increasing demand from employers, with 44% of large employers now covering obesity drugs, for comprehensive GLP-1 medication support. Dario's program aims to ensure judicious use of medications in conjunction with behavior change programs, driving sustainable clinical outcomes and maximizing return-on-investment. The solution supports members from medication initiation through long-term weight maintenance.
Steven Nelson, Chief Commercial Officer, stated that this collaboration completes Dario's end-to-end GLP-1 solution, positioning the company to capture more opportunities and deliver actionable insights to pharma partners. Dr. Omar Manejwala, Chief Medical Officer, emphasized the importance of continuous, personalized support for sustainable weight loss with GLP-1 medications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.